Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes

Overview

Journal J Diabetes Sci Technol

Specialty Endocrinology

Date 2025 Jan 8

PMID 39773006

Authors

Ji Yoon Kim

Jee Hee Yoo

Nam Hoon Kim

Jae Hyeon Kim

Affiliations

Soon will be listed here.

Abstract

Background: The glycemia risk index (GRI) is a novel composite continuous glucose monitoring (CGM) metric composed of hypoglycemia and hyperglycemia components and is weighted toward extremes. This study aimed to investigate the association between GRI and the risk of albuminuria in type 1 diabetes.

Methods: The 90-day CGM tracings of 330 individuals with type 1 diabetes were included in the analysis. Glycemia risk index was divided into five risk zones (A-E), and hypoglycemia and hyperglycemia components were divided into quintiles. Albuminuria was defined as a spot urine albumin-to-creatinine ratio ≥30 mg/g. Associations of albuminuria with GRI and its hypoglycemia and hyperglycemia components were estimated.

Results: Mean GRI and glycated hemoglobin (HbA1c) were 40.9 ± 21.3 and 7.3 ± 1.0%, respectively, and the overall prevalence of albuminuria was 17.6%. Prevalence of albuminuria differed significantly by GRI zone ( = .023). In logistic regression analysis, the adjusted odds ratio (OR) of albuminuria per increase in the GRI zone was 1.70 (95% confidence interval [CI]: 1.19-2.41) after adjusting for various factors affecting albuminuria. The association remained significant after adjusting for achievement of the recommended target of time in range (70-180 mg/dL; >70%) or HbA1c (<7%). The hyperglycemia component of GRI was also associated with albuminuria, and the association remained significant even after adjusting for HbA1c level itself (adjusted OR 1.44, 95% CI: 1.05-1.98).

Conclusions: Glycemia risk index is significantly associated with albuminuria in individuals with type 1 diabetes.

References

Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R . Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016; 388(10057):2254-2263. DOI: 10.1016/S0140-6736(16)31535-5. View

Tamborlane W, Beck R, Bode B, Buckingham B, Peter Chase H, Clemons R . Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359(14):1464-76. DOI: 10.1056/NEJMoa0805017. View

Anders H, Huber T, Isermann B, Schiffer M . CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018; 14(6):361-377. DOI: 10.1038/s41581-018-0001-y. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Yoo J, Kim J . Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control. Diabetes Metab J. 2021; 45(5):795. PMC: 8497919. DOI: 10.4093/dmj.2021.0256. View

Kim N, Seo M, Jung J, Han K, Kim M, Kim N . 2023 Diabetic Kidney Disease Fact Sheet in Korea. Diabetes Metab J. 2024; 48(3):463-472. PMC: 11140395. DOI: 10.4093/dmj.2023.0310. View

Baek J, Lee W, Lee B, Kim S, Kim G, Jin S . Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus. Diabetes Metab J. 2020; 45(1):46-54. PMC: 7850868. DOI: 10.4093/dmj.2019.0134. View

Yu J, Lee S, Kim M . Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. Endocrinol Metab (Seoul). 2022; 37(1):26-37. PMC: 8901964. DOI: 10.3803/EnM.2022.105. View

Wang Y, Lu J, Ni J, Wang M, Shen Y, Lu W . Association between glycaemia risk index (GRI) and diabetic retinopathy in type 2 diabetes: A cohort study. Diabetes Obes Metab. 2023; 25(9):2457-2463. DOI: 10.1111/dom.15068. View

10.

Kim J, Kim N . Initial Combination Therapy in Type 2 Diabetes. Endocrinol Metab (Seoul). 2023; 39(1):23-32. PMC: 10901659. DOI: 10.3803/EnM.2023.1816. View

11.

Huang X, Zhou Y, Xu B, Sun W, Lin L, Sun J . Glycated haemoglobin A1c is associated with low-grade albuminuria in Chinese adults. BMJ Open. 2015; 5(8):e007429. PMC: 4538277. DOI: 10.1136/bmjopen-2014-007429. View

12.

. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287(19):2563-9. PMC: 2622728. DOI: 10.1001/jama.287.19.2563. View

13.

Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S . Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism. 2003; 52(5):605-8. DOI: 10.1053/meta.2003.50096. View

14.

Choi J, Lee K, Moon J, Chon S, Kim D, Kim H . 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023; 47(5):575-594. PMC: 10555541. DOI: 10.4093/dmj.2023.0282. View

15.

Tumminia A, Crimi S, Sciacca L, Buscema M, Frittitta L, Squatrito S . Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial. Diabetes Metab Res Rev. 2014; 31(1):61-8. DOI: 10.1002/dmrr.2557. View

16.

Jafri R, Balliro C, El-Khatib F, Maheno M, Hillard M, ODonovan A . A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense Continuous Glucose Monitoring Devices in a Home-Use Study of Subjects with Type 1 Diabetes. Diabetes Technol Ther. 2020; 22(11):846-852. DOI: 10.1089/dia.2019.0449. View

17.

Yun J, Ko S, Ko S, Song K, Ahn Y, Yoon K . Presence of macroalbuminuria predicts severe hypoglycemia in patients with type 2 diabetes: a 10-year follow-up study. Diabetes Care. 2012; 36(5):1283-9. PMC: 3631817. DOI: 10.2337/dc12-1408. View

18.

Kim J, Jin S, Sim K, Kim B, Cho J, Moon J . Continuous glucose monitoring with structured education in adults with type 2 diabetes managed by multiple daily insulin injections: a multicentre randomised controlled trial. Diabetologia. 2024; 67(7):1223-1234. DOI: 10.1007/s00125-024-06152-1. View

19.

Van Beers C, DeVries J, Kleijer S, Smits M, Geelhoed-Duijvestijn P, Kramer M . Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016; 4(11):893-902. DOI: 10.1016/S2213-8587(16)30193-0. View

20.

Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R . The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012; 55(12):3155-62. PMC: 3483098. DOI: 10.1007/s00125-012-2708-9. View